| Name | Title | Contact Details |
|---|
Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.
Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you`re creative, collaborative and passionate about making a difference in the lives of patients, join us!